The real‐world impact of dosing of methadone and buprenorphine in retention on opioid agonist therapies in Ukraine.

Background and Aims: Ukraine's HIV epidemic remains concentrated among opioid‐dependent people who inject drugs (PWID) where opioid agonist therapies (OAT) like methadone (MMT) and buprenorphine (BMT) maintenance treatments are the most cost‐effective HIV prevention strategies, but remain under‐scal...

Descripción completa

Detalles Bibliográficos
Publicado en:Addiction Vol. 116; no. 1; pp. 83 - 94
Autores principales: Farnum, Scott O., Makarenko, Iuliia, Madden, Lynn, Mazhnaya, Alyona, Marcus, Ruthanne, Prokhorova, Tanya, Bojko, Martha J., Rozanova, Julia, Dvoriak, Sergii, Islam, Zahedsul, Altice, Frederick L.
Formato: research tables/charts Journal Article
Publicado: Wiley-Blackwell Jan2021
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=147905374&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 147905374
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        09652140
        AIO
      jtl: Addiction
      issn: 09652140
      maglogo: Y
    pubinfo:
      dt: Jan2021
      vid: 116
      iid: 1
      pid: 480
      pub: Wiley-Blackwell
      place: Malden, Massachusetts
    artinfo:
      ui:
        147905374
        145837898
        147905374
        147905374
        10.1111/add.15115
        147905374
      ppf: 83
      ppct: 11
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: C
          – @attributes:
              type: P
      tig:
        atl: The real‐world impact of dosing of methadone and buprenorphine in retention on opioid agonist therapies in Ukraine.
      aug:
        au:
          Farnum, Scott O.
          Makarenko, Iuliia
          Madden, Lynn
          Mazhnaya, Alyona
          Marcus, Ruthanne
          Prokhorova, Tanya
          Bojko, Martha J.
          Rozanova, Julia
          Dvoriak, Sergii
          Islam, Zahedsul
          Altice, Frederick L.
        affil: APT Foundation, New Haven CT,, USA
      sug:
        subj:
          Substance Dependence Drug Therapy
          Methadone Administration and Dosage
          Buprenorphine Administration and Dosage
          Decision Making
          Prescribing Patterns
          Human
          Ukraine
          Female
          Male
          Prospective Studies
          Nonexperimental Studies
          Time Factors
          Cox Proportional Hazards Model
          Regression
          Log-Rank Test
          Descriptive Statistics
          Odds Ratio
          Confidence Intervals
          Implementation Science
          Female
          Male
      ab: Background and Aims: Ukraine's HIV epidemic remains concentrated among opioid‐dependent people who inject drugs (PWID) where opioid agonist therapies (OAT) like methadone (MMT) and buprenorphine (BMT) maintenance treatments are the most cost‐effective HIV prevention strategies, but remain under‐scaled. This study aimed to measure the association between dose and type of OAT prescribed and treatment retention. Design Observational longitudinal cohort study. Participants and Setting: Patients (n = 15 290) prescribed OAT throughout Ukraine from 2004 through 2016. Measurements Data were analyzed using time–event strategies to estimate cumulative treatment retention, defined as time to OAT discontinuation. Cumulative retention proportions at 1, 12 and 36 months were assessed for outcomes. Cox regression with log‐rank likelihood assessed independent predictors of treatment discontinuation. Findings The proportion prescribed high (MMT: > 85 mg; BMT: ≥ 16 mg), medium (MMT: > 40–85 mg; BMT: > 6–15 mg) and low (MMT: ≤ 40 mg; BMT: ≤ 6 mg) dosages was 25, 43 and 32%, respectively. Retention was significantly higher for BMT than MMT both at 12 (89 versus 75%) and 36 months (80 versus 56%). Although dosing levels for BMT did not influence retention, increasing dosages for MMT were significantly associated with higher retention rates at 1 (90, 96, 99%), 12 (59, 78, 91%) and 36 (34, 59, 79%) months, respectively. Independent predictors associated with 12‐month OAT discontinuation were medium [adjusted hazard ratio (aHR) = 2.23; 95% confidence limit (CL) = 1.95–2.54] and low (aHR = 4.96; 95% CL = 4.37–5.63) OAT dosage relative to high dosage, male sex (aHR = 1.27; 95% CL = 1.14–1.41), MMT relative to BMT prescription (aHR = 1.57; 95% CL = 1.32–1.87) and receiving OAT in general (aHR = 1.22; 95% CL = 1.02–1.46) or tuberculosis (aHR = 1.43; 95% CL = 1.10–1.85) hospitals, relative to specialty addiction treatment and AIDS center settings. Lower dosages contributed more to dropout especially at 1 month (aHR 3.12; 95% CL = 2.21–4.41 and aHR 7.71; 95% CL = 5.51–10.79 for medium and low dosages, respectively). Younger age was significantly associated with OAT discontinuation only at 36 months (aHR = 1.08; 95% CI = 1.02–1.15). Conclusions: Higher dosages of opioid agonist therapies, especially for methadone maintenance treatment patients, appear to be associated with higher levels of treatment retention in Ukraine.
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N